QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - NYSE:QGEN - NL0015002CX3 - Common Stock
44.16 USD
-1.52 (-3.33%)
44.16 USD
0 (0%)
Overall QGEN gets a fundamental rating of 6 out of 10. We evaluated QGEN against 58 industry peers in the Life Sciences Tools & Services industry. QGEN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. QGEN is not valued too expensively and it also shows a decent growth rate. These ratings would make QGEN suitable for quality investing!
1. Profitability
1.1 Basic Checks
QGEN had positive earnings in the past year.
In the past year QGEN had a positive cash flow from operations.
Each year in the past 5 years QGEN has been profitable.
Each year in the past 5 years QGEN had a positive operating cash flow.
1.2 Ratios
QGEN has a better Return On Assets (6.41%) than 84.48% of its industry peers.
QGEN's Return On Equity of 10.65% is amongst the best of the industry. QGEN outperforms 82.76% of its industry peers.
QGEN has a better Return On Invested Capital (8.66%) than 82.76% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 13.50%.
The last Return On Invested Capital (8.66%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROIC | 8.66% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
QGEN has a Profit Margin of 18.30%. This is amongst the best in the industry. QGEN outperforms 91.38% of its industry peers.
QGEN's Profit Margin has declined in the last couple of years.
QGEN has a better Operating Margin (26.86%) than 94.83% of its industry peers.
QGEN's Operating Margin has improved in the last couple of years.
QGEN has a Gross Margin of 64.18%. This is amongst the best in the industry. QGEN outperforms 86.21% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
QGEN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
The debt/assets ratio for QGEN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.97 indicates that QGEN is not in any danger for bankruptcy at the moment.
QGEN's Altman-Z score of 3.97 is fine compared to the rest of the industry. QGEN outperforms 74.14% of its industry peers.
QGEN has a debt to FCF ratio of 2.91. This is a good value and a sign of high solvency as QGEN would need 2.91 years to pay back of all of its debts.
QGEN has a Debt to FCF ratio of 2.91. This is amongst the best in the industry. QGEN outperforms 81.03% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that QGEN is not too dependend on debt financing.
QGEN has a Debt to Equity ratio of 0.25. This is comparable to the rest of the industry: QGEN outperforms 51.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Altman-Z | 3.97 |
ROIC/WACC1.15
WACC7.55%
2.3 Liquidity
QGEN has a Current Ratio of 1.61. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of QGEN (1.61) is worse than 63.79% of its industry peers.
QGEN has a Quick Ratio of 1.35. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.35, QGEN is not doing good in the industry: 65.52% of the companies in the same industry are doing better.
QGEN does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.20%, which is quite good.
Measured over the past years, QGEN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.40% on average per year.
Looking at the last year, QGEN shows a small growth in Revenue. The Revenue has grown by 5.15% in the last year.
QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.32% yearly.
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
3.2 Future
QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.78% yearly.
Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.82% on average per year.
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.78%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.82%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.79 indicates a rather expensive valuation of QGEN.
Compared to the rest of the industry, the Price/Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 84.48% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.03, QGEN is valued a bit cheaper.
A Price/Forward Earnings ratio of 17.01 indicates a rather expensive valuation of QGEN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 86.21% of the companies listed in the same industry.
QGEN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.27, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.79 | ||
| Fwd PE | 17.01 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 94.83% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 86.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.31 | ||
| EV/EBITDA | 13.81 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.2
PEG (5Y)2.24
EPS Next 2Y8.08%
EPS Next 3Y8.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.54%, QGEN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.49, QGEN pays a better dividend. On top of this QGEN pays more dividend than 94.83% of the companies listed in the same industry.
With a Dividend Yield of 0.54, QGEN pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
5.2 History
QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.08%
EPS Next 3Y8.5%
44.16
-1.52 (-3.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.95%
Inst Owner Change-7.64%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap9.58B
Revenue(TTM)2.04B
Net Income(TTM)373.39M
Analysts74.17
Price Target52.09 (17.96%)
Short Float %2.82%
Short Ratio5.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.7%
Min EPS beat(2)-2.4%
Max EPS beat(2)7.8%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.51%
EPS beat(12)8
Avg EPS beat(12)3.69%
EPS beat(16)12
Avg EPS beat(16)5.44%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.16%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-0.41%
Revenue beat(16)7
Avg Revenue beat(16)0.85%
PT rev (1m)-1.37%
PT rev (3m)1.07%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)0.3%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)1.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.79 | ||
| Fwd PE | 17.01 | ||
| P/S | 4.69 | ||
| P/FCF | 19.31 | ||
| P/OCF | 14.18 | ||
| P/B | 2.73 | ||
| P/tB | 14.98 | ||
| EV/EBITDA | 13.81 |
EPS(TTM)2.35
EY5.32%
EPS(NY)2.6
Fwd EY5.88%
FCF(TTM)2.29
FCFY5.18%
OCF(TTM)3.11
OCFY7.05%
SpS9.41
BVpS16.17
TBVpS2.95
PEG (NY)2.2
PEG (5Y)2.24
Graham Number29.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.41% | ||
| ROE | 10.65% | ||
| ROCE | 11.67% | ||
| ROIC | 8.66% | ||
| ROICexc | 10.87% | ||
| ROICexgc | 46.44% | ||
| OM | 26.86% | ||
| PM (TTM) | 18.3% | ||
| GM | 64.18% | ||
| FCFM | 24.31% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 2.91 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 94.78% | ||
| Cap/Sales | 8.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.61% | ||
| Profit Quality | 132.83% | ||
| Current Ratio | 1.61 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 3.97 |
F-Score8
WACC7.55%
ROIC/WACC1.15
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.78%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.82%
EBIT growth 1Y21.82%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.27%
EBIT Next 3Y22.23%
EBIT Next 5Y15.78%
FCF growth 1Y31.74%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y29.99%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
What is the valuation status of QIAGEN N.V. (QGEN) stock?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What are the PE and PB ratios of QIAGEN N.V. (QGEN) stock?
The Price/Earnings (PE) ratio for QIAGEN N.V. (QGEN) is 18.79 and the Price/Book (PB) ratio is 2.73.